pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2007-0-6-12-22pulmo-1994Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESРекомендации Франкоязычного общества пульмонологии по ведению злокачественной мезотелиомы плеврыGuidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesotheliomaШеперельА.ScherpereelA.
ПарижЛилль
Институт Пастера; Отделение легочной и торакальной онкологии Университетского госпиталяФранцияFrench Speaking Society for Chest Medicine (SPLF), Experts GroupFrance200728122007061222Copyright © Шеперель А., 20072007Шеперель А.Scherpereel A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1994
.
.
ReferencesRobinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005; 366: 397–408.Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005; 366: 397–408.Chang K.C., Leung C.C. Malignant mesothelioma: a minor issue about gender ratio and a major issue about regulatory policy. Respir. Med. 2006; 100: 1123–1124.Chang K.C., Leung C.C. Malignant mesothelioma: a minor issue about gender ratio and a major issue about regulatory policy. Respir. Med. 2006; 100: 1123–1124.Ordonez N.G. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am. J. Surg. Pathol. 2003; 27: 1031–1051.Ordonez N.G. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am. J. Surg. Pathol. 2003; 27: 1031–1051.Pass H.I., Vogelzang N., Hahn S., Carbone M. Malignant pleural mesothelioma. Curr. Probl. Cancer. 2004; 28: 93–174.Pass H.I., Vogelzang N., Hahn S., Carbone M. Malignant pleural mesothelioma. Curr. Probl. Cancer. 2004; 28: 93–174.West S.D., Foord T., Davies R.J. Needle-track metastases and prophylactic radiotherapy for mesothelioma. Respir. Med. 2006; 100: 1037–1040.West S.D., Foord T., Davies R.J. Needle-track metastases and prophylactic radiotherapy for mesothelioma. Respir. Med. 2006; 100: 1037–1040.Societe de Pneumologie de Langue Francaise. The French language Society of Pneumology guidelines on the pleural mesothelioma. Rev. Mal. Respir. 2006; 23 (suppl. 3): 6S806S92. (Copyright SPLF, Paris 2006, all rights reserved).Societe de Pneumologie de Langue Francaise. The French language Society of Pneumology guidelines on the pleural mesothelioma. Rev. Mal. Respir. 2006; 23 (suppl. 3): 6S806S92. (Copyright SPLF, Paris 2006, all rights reserved).Travis W.D., Brambilla E., Mыller2Hermelink H.K., Harris C. Tumours of the lung, pleura, thymus and heart. Lyon: WHO, IARC Press; 2004.Travis W.D., Brambilla E., Mыller2Hermelink H.K., Harris C. Tumours of the lung, pleura, thymus and heart. Lyon: WHO, IARC Press; 2004.Vogelzang N.J., Rusthoven J.J., Symanowski J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21: 2636–2644.Vogelzang N.J., Rusthoven J.J., Symanowski J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21: 2636–2644.van Meerbeeck J.P., Gaafar R., Manegold C. et al. European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005; 23: 6881–6889.van Meerbeeck J.P., Gaafar R., Manegold C. et al. European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005; 23: 6881–6889.Bottomley A., Gaafar R., Manegold C. et al. EORTC LungCancer Group; National Cancer Institute, Canada. Shortterm treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J. Clin. Oncol. 2006; 24: 1435–1442.Bottomley A., Gaafar R., Manegold C. et al. EORTC LungCancer Group; National Cancer Institute, Canada. Shortterm treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J. Clin. Oncol. 2006; 24: 1435–1442.O’Brien M.E., Watkins D., Ryan C., Priest K., Corbishley C., Norton A., et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann. Oncol. 2006; 17: 270–275.O’Brien M.E., Watkins D., Ryan C., Priest K., Corbishley C., Norton A., et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann. Oncol. 2006; 17: 270–275.
The authors declare that there are no conflicts of interest present.